Get the Stockscreener App
33.74
2.00%
-0.69
After Hours:
34.00
0.26
+0.77%
Harrow Inc stock is traded at $33.74, with a volume of 1.06M.
It is down -2.00% in the last 24 hours and down -3.41% over the past month.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.
See More
Previous Close:
$34.43
Open:
$34.64
24h Volume:
1.06M
Relative Volume:
2.31
Market Cap:
$1.24B
Revenue:
$154.15M
Net Income/Loss:
$-33.58M
P/E Ratio:
-35.15
EPS:
-0.96
Net Cash Flow:
$-20.74M
1W Performance:
+0.96%
1M Performance:
-3.41%
6M Performance:
+6.27%
1Y Performance:
-6.12%
1-Day Range:
$33.39
$34.95
1-Week Range:
$32.30
$35.33
52-Week Range:
$20.85
$59.23
Harrow Inc Stock (HROW) Company Profile
Name
Harrow Inc
Sector
Phone
615.733.4731
Address
1A BURTON HILLS BLVD, NASHVILLE, CA
Compare HROW with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HROW
Harrow Inc
|
33.74 | 1.26B | 154.15M | -33.58M | -20.74M | -0.96 |
|
ZTS
Zoetis Inc
|
149.02 | 65.30B | 9.39B | 2.61B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.43 | 45.60B | 29.98B | 958.27M | 5.31B | 0.2964 |
|
HLN
Haleon Plc Adr
|
9.47 | 42.82B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.42 | 18.78B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
300.43 | 13.64B | 2.99B | 1.21B | 1.13B | 25.06 |
Harrow Inc Stock (HROW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-11-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-12-25 | Initiated | BTIG Research | Buy |
| Jun-10-25 | Initiated | William Blair | Outperform |
| Feb-06-25 | Initiated | H.C. Wainwright | Buy |
| Dec-04-24 | Reiterated | B. Riley Securities | Buy |
| Apr-11-24 | Initiated | Craig Hallum | Buy |
| Sep-08-22 | Resumed | B. Riley Securities | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Sep-24-21 | Initiated | Aegis Capital | Buy |
| Jul-02-21 | Initiated | Ladenburg Thalmann | Buy |
View All
Harrow Inc Stock (HROW) Latest News
Harrow Health’s Growth Streak Sets High Hopes For 2025 - Finimize
Harrow: Q2 Earnings Snapshot - San Antonio Express-News
Harrow Health Reports Strong Q2 2025 Financial Results - TipRanks
Earnings Flash (HROW) Harrow, Inc. Posts Q2 Diluted EPS $0.24 per Share - MarketScreener
Earnings Flash (HROW) Harrow, Inc. Reports Q2 Revenue $63.7M, vs. FactSet Est of $66.0M - MarketScreener
Harrow Announces Second-Quarter 2025 Financial Results - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc.HROW - WV News
Harrow Inc (HROW) Q2 2025: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Will Harrow's (HROW) Recent Conference Engagements Reveal More About Its Competitive Position? - simplywall.st
Harrow Inc Q2 2025 Earnings Report Preview: Revenue, Earnings, and Price Targets - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW - Bluefield Daily Telegraph
Harrow 8.625% 20260430 HROWL Q2 2025 Earnings Preview Upside Anticipated on Strong Educational Expansion - AInvest
A Preview Of Harrow's Earnings - 富途牛牛
Harrow, Inc. shares fall 1.82% intraday after announcing participation in H.C. Wainwright’s 5th Annual Ophthalmology Conference. - AInvest
Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Co - GuruFocus
Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference - The Manila Times
Harrow Executives Reveal Future of Eye Care: Double Feature at Major Ophthalmology Conference - Stock Titan
Insider Backed Growth Companies To Watch Now - simplywall.st
Harrow (HROW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
How volatile is Harrow Inc. stock compared to the marketDiscover the next big stock winners - Jammu Links News
What makes Harrow Inc. stock price move sharplyAchieve breakthrough profits with expert advice - Jammu Links News
Is Harrow Inc. a growth stock or a value stockUncover the best stocks for explosive growth - Jammu Links News
What drives Harrow Inc. stock priceHigh-performance stocks for savvy investors - Jammu Links News
What is the dividend policy of Harrow Inc. stockInvest smarter with comprehensive market analysis - Jammu Links News
What is Harrow Inc. company’s growth strategyBuild wealth faster with expert stock picks - Jammu Links News
While Harrow (NASDAQ:HROW) Shareholders Have Made 432% in 5 Years, Increasing Losses Might Now Be Front of Mind as Stock Sheds 14% This Week - 富途牛牛
Published on: 2025-08-03 17:16:02 - Jammu Links News
What are the latest earnings results for Harrow Inc.Invest confidently with professional guidance - Jammu Links News
What are Harrow Inc. company’s key revenue driversInvest confidently with expert support - Jammu Links News
What analysts say about Harrow Inc. stockDiscover stocks with explosive growth potential - Jammu Links News
What catalysts could drive Harrow Inc. stock higher in 2025Unlock daily stock market insights for success - Jammu Links News
Does Harrow Inc. stock perform well during market downturnsAccess exclusive market insights for free - Jammu Links News
How does Harrow Inc. generate profit in a changing economyDiscover hidden gems in the stock market - Jammu Links News
What is the risk reward ratio of investing in Harrow Inc. stockMaximize returns with timely market signals - Jammu Links News
What are analysts’ price targets for Harrow Inc. in the next 12 monthsUnlock superior stock analysis tools - Jammu Links News
What markets is Harrow Inc. expanding into Is Zedge Inc. stock a good long term investment optionAdvanced Screener Growth Plan For Every Investor - Jammu Links News
When is Harrow Inc. stock expected to show significant growthPre Market Insights For Beginners - Jammu Links News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW - GlobeNewswire Inc.
Is Harrow Inc. stock overvalued or undervaluedBeginner Investor Ideas For Smart Trading - jammulinksnews.com
What are the technical indicators suggesting about Harrow Inc.AI Powered Strategy For 2025 - Jammu Links News
What Fibonacci levels say about Harrow Inc. reboundTrade Timing Strategy With Technical Data Explained - metal.it
Candlestick Reversal Detected on Harrow Inc.’s ChartSwing Setup With Technical Confirmation Explained - metal.it
Harrow to Release Q2 2025 Financial Results on August 11, 2025 - AInvest
Can Harrow Inc. Outperform Peers After Recent PullbackStock Portfolio Allocation Guidance for Volatile Markets - metal.it
Institutional owners may ignore Harrow, Inc.'s (NASDAQ:HROW) recent US$81m market cap decline as longer-term profits stay in the green - simplywall.st
Harrow To Report Second Quarter 2025 Financial Results After Market Close on August 11, 2025 - GlobeNewswire
Harrow Inc Stock (HROW) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
2.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):